Article
Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
Scientific reports - 6 Nov 2017
Hou Helei, Yang Xiaonan, Zhang Jinping, Zhang Zhe, Xu Xiaomei, Zhang Xiaoping, Zhang Chuantao, Liu Dong, Yan Weihua, Zhou Na, Zhu Hongmei, Qian Zhaoyang, Li Zhuokun, Zhang Xiaochun
Abstract excerpt
Next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) assays have provided a new method of identifying tumor-driving genes in patients with advanced non-small cell lung carcinoma (NSCLC), especially in those whose cancer tissues are unavailable or in those that have acquired treatment resistance. Here, we describe a total of 119 patients with advanced EGFR-TKI-naive NSCLC and 15 EGFR-TKI-resistant...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Circulating Tumor DNA
- Cohort Studies
- Disease Progression
- Drug Resistance, Neoplasm